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Abstract: The combined oral contraceptive pill (COC) consisting of drospirenone 3 mg/ethinyl 
estradiol 20 µg (3 mg DRSP/20 µg EE-24/4) supplies 24 days of pills with hormones followed 
by 4 days of hormone-free pills. This regimen is called the 24/4 regimen. The progesterone 
component of this oral contraceptive pill (OCP), drospirenone (DRSP), is a fourth-generation 
progestin that has potent progestogenic, antimineralocorticoid, and antiandrogenic activity, 
which are unique characteristics compared with the other progestogens contained in most of the 
other OCPs currently marketed. This formulation, in addition to being an effective long-term 
OCP, has the additional medical benefit of providing a good parallel treatment for premenstrual 
dysphoric disorder and moderate acne. The effectiveness of 3 mg DRSP/20 µg EE-24/4, its 
tolerability and safety, and its additional non-contraceptive benefits are discussed.
Keywords: drospirenone, premenstrual dysphoric disorder, acne vulgaris, contraception, 
antimineralocorticoid activity, antiandrogenic activity
Introduction to the 3 mg DRSP/20 µg EE (24/4) oral 
contraceptive pill
Between 1973 and 1974 the US Food and Drug Administration first approved several 
low dose pills. By 1975, no pill recommended for contraception had more than 50 µg of 
estrogen, with most containing estrogen levels in the range of 20 to 30 µg. A decrease 
in the progesterone component to 1 mg or less as well as different progestins were 
also introduced into the oral contraceptive pill (OCP) formulations. Today, newer 
OCPs have not only altered estrogen and progestin levels, but also have varied 
the number of active pills. These changes in OCP have had the goal of acceptable 
contraceptive efficacy with minimal side effects and risks. In more recent years, certain 
OCP formulations have been prescribed to treat various medical conditions, such as 
premenstrual dysphoric disorder (PMDD), moderate acne vulgaris, polycystic ovarian 
syndrome and hirsuitism.
There are 60 million women of reproductive age in the US, approximately 64% of 
whom use some method of contraception.1 Oral contraceptives are the most popular 
reversible method of contraception in America (26.9%) and second only in popularity 
to the combined permanent sterilization of women (27.7%) and vasectomies (10.9%). 
Fifty-three percent of US contraception users aged 15 to 24 use OCPs for their high 
efficacy, ease of use, minimal side effects and good cycle control.2
However, effective hormonal contraception may be discontinued by sexually 
active, reproductive-age women despite their continued need due to the intolerability 
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of side effects. Bleeding irregularities, nausea, headaches 
and fluid retention related symptoms such as breast tender-
ness and bloating are frequently the side effects that cause 
discontinuance of OCP use.3
The fourth-generation progestins used in OCPs were 
introduced to the market in an attempt to minimize the 
negative side effects of progestins that were used earlier in 
OCPs and to address the other medical conditions that they 
could be effective in treating.
PMDD is included in the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV).4 Women with 
PMDD report mood symptoms such as lability and 
behavioral symptoms such as changes in eating patterns. 
PMDD also involves physical symptoms such as breast 
tenderness, edema and/or headaches. PMDD symptoms 
occur during the last week of the luteal phase of the 
menstrual cycle and resolve in the week after menses.4 
Using the formulation of drospirenone 3 mg/ethinyl 
estradiol 20 µg (3 mg DRSP/20 µg EE-24/4) in women 
with PMDD is desirable as the progestin may ameliorate 
physical symptoms and the shortened hormone-free interval 
(4 hormone-free days) will provide greater suppression of 
follicle development and a more stable level of exogenous 
hormones throughout the cycle.3 A multicenter, double-
blind, placebo-controlled crossover study showed that 
this OCP formulation decreased the mood, behavioral and 
physical symptoms of PMDD.5 Another study looking at 
the efficacy of this combination OCP in the treatment of 
PMDD drew similar conclusions.6
Acne vulgaris is caused by an overproduction of androgen 
by the sebaceous glands, which can lead to increased sebum 
production and acne. Moderate acne vulgaris is the most 
common form of acne and patients present with various types 
of lesions with whiteheads, papules and pustules. Severe 
acne on the other hand is characterized by the presence of 
nodules and cysts on the dermatologic surfaces. The benefit 
of treating moderate acne vulgaris is important, since the 
condition is often found in young adults and the lesions that 
are obvious, particularly on the face and neck, can lead to 
negative psychosocial consequences.7 The main hormonal 
mechanism by which acne may be treated by OCP is through 
the effects of the estrogen component. That is, the estrogen 
in the OCP augments the levels of the sex hormone binding 
globulin (SHBG), which in turn increases the binding of 
free testosterone. Therefore, there is less free androgen in 
the circulation, to exert its action on the sebaceous glands. 
Drospirenone has another hormonal mechanism: that of an 
antiandrogenic hormone, which exerts its progestational and 
antimineralocorticoid effects by competitively inhibiting 
and binding androgens to its receptors. This mechanism 
would explain the reduction in sebum excretion rates and 
lesion counts.7
There have been no clinical trials exploring the role 
of 3 mg DRSP/20 µg EE-24/4 in PCOS, patients. It can 
be hypothesized that this combination of hormones would 
be effective in reducing adrenal androgens to the point of 
clinical significance. Although this formulation has not 
been studied in this condition, there are some data on a 
similar formulation that suggest that it may be effective. 
This formulation may be effective in the treatment of 
hyperandrogenism, not only causing blockade of ovarian 
steroid production but also by acting on the adrenals to 
reduce adrenal androgen synthesis.8 In one prospective 
study, a 30 µg EE with 3 mg DRSP (21/7) OCP was shown 
to affect steroid genesis by reducing synthesis and release 
of androgens in response to adrenocorticotropic hormone 
(ACTH).
Since most oral contraceptives, such as levonorgestrel, 
norgestrel, norethindrone, and desogestrel, use synthetic 
progestins derived from 19 nortestosterone or 17 alpha 
hydroxyprogesterone derivatives, they are not structurally 
similar to aldosterone and therefore do not possess antimin-
eralocorticoid effects. These progestins do not antagonize 
the salt-retaining effect of estrogen, which may contribute 
to weight gain and increased blood pressure seen in 
some women using OCPs. On the other hand, drospirenone 
may prevent the sodium and water retention via the renin-
angiotensin-aldosterone system.9
DRSP is similar to progesterone in its ability to have 
potent antiandrogenic and antimineralocorticoid activities.8 
The only other DRSP containing OCP that is currently 
marketed is the OCP with DRSP 3 mg and EE 30 µg. 
The difference between 3 mg DRSP/20 µg EE-24/4 and 
3 mg DRSP/30 µg EE-21/7 is that each tablet in the prior 
formulation contains a lower dose of EE (20 vs 30 µg) and 
has a shorter hormone-free interval (4 days vs 7 days). The 
shorter hormone-free interval leads to a greater suppression 
of follicle development and a more stable hormone time 
frame than the traditional regimens of 21-day hormone-
containing pill and 7 days placebo. As expected, greater 
pituitary and ovarian suppression are seen with the shorter 
hormone-free interval.9 Because of this effect, the 24/4 
regimen should better alleviate symptoms such as pelvic 
pain, headaches, bloating and breast tenderness that are 
commonly reported during the 7 days of placebo pills by 
women taking a regimen of 21 days of active pills followed Patient Preference and Adherence 2009:3 261
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Figure 1 Structure of drospirenone and ethinyl estradiol.
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by seven hormone free pill days (21/7 regimen). Extending 
the days on active treatment reduces hormone withdrawal 
effects in most women since the fluctuations in hormone 
levels is minimal.10
Biochemical properties/chemistry
Drospirenone is a synthetic progestin with the molecular weight 
of 366.5 and the molecular formula of C24H30O3. Ethinyl estradiol 
is a synthetic estrogen with the molecular weight of 296.4 and 
the molecular formula of C20H24O2 (Bayer Pharmaceutical 
Company; http://dailymed.nlm.nih.gov/dailymed/drugInfo.
cfm?id=7949). The structural formulas are given in Figure 1.
Pharmacodynamics
The (24/7) oral contraceptive regimen has 24 active film-
coated tablets that contain 3 mg of drospirenone and 0.02 mg 
of EE. These hormones are stabilized in the tablet by betadex 
as a clathrate. The rest of the regimen consists of 4 inert film-
coated tablets.11 The drospirenone structure is an analogue 
of 17 alpha spironolactone.
The mechanism of action is through the suppression 
of gonadotropin release from the hypothalamus. With 
suppression of gonadotropin release, ovarian stimulation 
and follicular maturation do not occur, and the estradiol 
levels are low due to diminished follicular production. 
The follicles are the major producers of estradiol and with 
a sparsity of follicular maturation, estradiol production 
therefore plummets.
In the typical 21/7 OCP regimen, there is less gonadotropin 
suppression and follicular maturation may occur. Since the 
pill-free interval is only 7 days, in most women the follicle 
does not mature to the point of ovulation, and therefore 
most OCP cycles are anovulatory. Since the OCP also has 
a progestin for at least 21 day, the cervical mucus is also 
altered. With estrogen alone, the cervical mucus is thin, 
clear, and copious with Spinnbarkeit noted. Once a progestin 
is introduced, the cervical mucus becomes thick, sticky, 
pasty and scant. It is this progestin-affected cervical mucus 
in the combination OCP that produces an environment that 
makes it difficult for sperm to enter the uterus. The progestin 
also alters motility of the uterus and oviduct as the normal 
transport of both the ovulated ova traveling down the fallopian 
tube and the sperm that are traveling up the fallopian tube 
to fertilize this ova is interrupted. Progestins also alter the 
endometrium, such that the glandular production of glycogen 
is diminished.12 In addition to these progestin effects, the 
drospirenone, which is similar to endogenous progesterone, 
contains antimineralocorticoid, progestogenic and antian-
drogenic properties. Drospirenone increases urinary sodium 
and aldosterone excretion and causes reversible increase in 
plasma aldosterone levels.2
Pharmacokinetics and metabolism
The pharmacokinetic profile of 3 mg DRSP/20 µg EE-24/4 has 
been studied preclinically and clinically.11 When evaluating 
a single tablet with DRSP only, the absolute bioavailability 
of DRSP is about 76%, a percentage measured after it 
undergoes first pass metabolism through the liver. The 
absolute bioavailability of EE (without the DRSP component) 
is approximately 40%, measured after the first pass, taking 
into consideration the presystemic conjugation. The absolute 
bioavailability of the combination tablet of 3 mg DRSP/20 µg 
EE tablet as ultilized in the currently marketed OCP has not 
been evaluated.11
These concentrations are reduced by 40% when the DRSP 
tablet or the EE tablet is taken with food. Food consumption 
affects the rate but not the extent of absorption and is not 
considered to be clinically important.Patient Preference and Adherence 2009:3 262
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EE, a synthetic hormone that is highly protein bound to 
albumin in the circulation, is metabolized in the liver as well 
as in the small bowel mucosa. EE metabolism is mainly by 
aromatic hydroxylation, which forms a wide variety of free 
and glucoronide or sulfate-conjugated metabolites. With 
2 hydroxylation by cytochrome P450 (CYP) 3A4 enzymes, 
this synthetic estrogen metabolite undergoes methylation 
and glucoronidation before it is excreted in the urine and 
feces.2,11
DRSP is highly bound to serum metabolites (approximately 
97%) but does not bind to sex hormone binding globulin 
(SHBG). It is metabolized mostly independently of P450 
enzymes, with a minor degree of metabolism by CYP3A4. 
The acid form of drospirenone and 4,5 dihydrodrospirenone-
3-sulfate are the two main metabolites, neither of which are 
pharmacologically active.2,11 In women with liver impairment 
the DRSP levels are approximately 3 times higher. In women 
with renal dysfunction, the DRSP levels are approximately 
37% higher.
Clinical efficacy, safety  
and tolerability
The primary efficacy clinical trial was a 1-year study 
that looked at the number of pregnancies that occurred in 
reproductive aged women using 3 mg DRSP/20 µg EE-24/4. 
This 1-year study recruited 1027 subjects who completed 
11,480 of 28-day cycles of use. The subjects, who were 
racially diverse, ranged in age from 17 from 36 years. The 
racial demographics of the cohort was: 87.8% Caucasian, 
4.6% Hispanic, 4.3% Black, 1.2% Asian and 2.1% other. Data 
at completion of the study reported the Pearl index as 1.41 per 
100 women-years of use. Twelve pregnancies occurred 
after the onset of treatment and within 14 days after the last 
dose of 3 mg DRSP/20 µg EE-24/4.13 Another multicenter 
trial primarily examined not only contraceptive efficacy 
but also evaluated tolerability and patient satisfaction.3 
These data showed a 99% contraception protection rate 
which is comparable to other low dose combined oral 
contraceptive pills (COCs). Of note, only 77 (7.5%) of 
the subjects discontinued the OCP due to adverse events. 
This number is favorable when compared to other OCP 
studies where the withdrawal rates due to adverse events are 
usually closer to 10% to 17%. Of the women who rated their 
overall satisfaction, 86% stated that they were satisfied or 
very satisfied with the OCP and 73% stated that they would 
continue this OCP if it were available.
Two multicenter, double-blind, randomized, placebo-
controlled studies on PMDD treatment efficacy of 3 mg 
DRSP/20 µg EE-24/4 were performed on women who met 
full criteria for PMDD, compared with the milder PMS. 
One study recruited n = 449 in a parallel group study.6 
In this study, there were two run in/qualification and three 
treatment cycles. Another PMDD study was done in which 
n = 64 women with PMDD were recruited. In these studies, 
the subjects’ symptoms were rated using the Daily Record of 
Severity of Problems Scale. With this scale, a measurement 
is collected on the severity of 21 PMDD symptoms, such 
as feeling depressed, mood swings, diminished interest, 
breast swelling and headache. Women in these studies 
were between 18 and 40 years with a diagnosis of PMDD 
and lacking other recognized psychiatric disorders. They 
also had to have regular menstrual cycles and have no 
contraindications to OCP use. The outcome of both studies 
showed a significant difference in mean luteal phase, total 
Daily Record of Severity of Problems between qualification 
cycles and treatment cycles with a greater than 50% decrease 
in premenstrual symptoms and improvement in quality of life 
in these women suffering from PMDD.14
The therapeutic efficacy of 3 mg DRSP/20 µg EE-24/4 in 
women with moderate acne vulgaris was also assessed. Two 
double-blind, randomized, placebo-controlled multicenter 
trials using this OCP were conducted.2 In these trials subjects 
with moderate acne vulgaris (minimal of 40 facial lesions) 
received 3 mg DRSP/20 µg EE-24/4 or placebo for six cycles. 
In addition to the moderate acne vulgaris, subjects had to be 
able to take the OCP, have had a menstrual cycle in the last 
3 months and a normal pap smear. The primary outcome con-
firmed the hypothesis that this formulation was more effective 
than placebo in reducing the severity of moderate acne.7
Drug interactions
As with other formulations, the effectiveness of this 
formulation may be decreased with rifampin use because 
rifampin increases the metabolism of EE. Contraceptive 
efficacy may also be decreased by some anticonvulsants such 
as phenobarbital, phenytoin and carbamazepine, as these 
drugs increase the metabolism of EE and some progestins. 
Some herbal medicines and vitamins also affect OCP 
effectiveness. St. John’s Wort (Hypericum perforatum), for 
example, may reduce OCP efficacy by inducing cytochrome 
P450 and p-glycoprotein transporter. Of interest, ascorbic 
acid in some studies has been shown to increase the plasma 
concentrations of some synthetic estrogens. Increase in 
the plasma concentrations of cyclosporine, prednisolone 
and theophylline have been reported with concomitant 
administration of OCPs.11Patient Preference and Adherence 2009:3 263
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Because of the DRSP structure, serum potassium levels 
may be slightly elevated in women taking 3 mg DRSP/20 µg 
EE-24/4, but this increase is usually not significant.
Other metabolic interactions with DRSP were also 
studied. In vitro and in vivo studies evaluating the 
cytochrome P450 enzymes were investigated. Also, the 
potential effect of DRSP on CYPC219 activity was investi-
gated in a clinical pharmacokinetic study using omeprazole 
as a marker substrate. These studies showed that DRSP did 
not inhibit CYP2C19 and CYP3A4 in vivo. Two additional 
clinical drug–drug interaction studies were performed using 
simvastatin and midazolam, which had similar results.
Studies on carbohydrate metabolism, lipid and hemostatic 
parameters showed that high density lipoprotein increases, 
and low density lipoprotein decreases, thus suggesting 
cardioprotective benefit. Blood glucose levels only slightly 
elevated, but were still within normal range. Hemostatic 
parameters showed an increase in the activation markers of 
thrombin and fibrin turnover, findings comparable to those 
observed with other COCs.10
Adverse events
While using 3 mg DRSP/20 µg EE-24/4 some side affects 
such as spotting, dysmenorrhea, vomiting, breast tenderness, 
clumsiness, nervousness and increased irritability were 
reported by subjects that led to study discontinuation.6 Other 
side effects reported include upper respiratory infection, 
metrorrhagia, headache, nausea, sinusitis, suspicious Pap 
smears and vaginal moniliasis.7 These adverse events 
reported with 3 mg DRSP/20 µg EE-24/4 were typical of 
hormonal contraceptive use and were generally mild to 
moderate in intensity.15
Conclusion
In summary, the regimen 3 mg DRSP/20 µg EE-24/4 is safe 
and efficacious as a contraceptive. It is well tolerated and 
provides additional, non-birth control/non-contraceptive 
benefits. This OCP significantly improved the physical 
and emotional symptoms in women who suffer from 
PMDD. It was also beneficial in the treatment of women 
with moderate acne vulgaris. In addition, this OCP has 
the potential for clinical use in women with PCOS and 
hirsutism.
expert opinion
why should fourth-generation progestins be used?
The goal of newer progestin formulations are to decrease side 
effects. These newer progestins are used to better address 
medical conditions such as PMDD that affect women’s 
health and psychosocial well-being and to provide efficacious 
contraception with the lowest doses of hormones. Clinically, 
DRSP appears to prevent sodium and water retention via the 
renin-angiotensin-aldosterone system (RAAS). This anti-
mineralocorticoid effect may decrease bloating, weight gain 
and blood pressure.
Together with the safety and efficacy evidence from 
clinical trials, it is evident that 3 mg DRSP/20 µg EE-24/4 
provides therapeutic efficacy that corresponded to 99% 
contraceptive protection.
Improving the tolerability of OCPs without affecting 
their efficacy or safety has been a big challenge over the 
years. Reduction of hormone-free days in 3 mg DRSP/20 µg 
EE-24/4 reduces the incidence of hormone withdrawal 
adverse effects and decreases the incidence of ovulation. 
It has a high overall user satisfaction rating, and provides 
a close to physiological bleeding pattern. Because it is well 
tolerated with a lower incidence of adverse effects, we can 
extrapolate increased compliance.
Additional medical benefits were seen with PMDD and 
moderate acne vulgaris (the most common form of acne 
which is considered to decrease the quality of life in many 
young women). DRSP in this particular regimen offers 
extended days of acne treatment because of its long half-life 
compared to that of traditional OCPs. The anti-androgenic 
effects are stronger because DRSP is a fourth-genera-
tion progestin. It has more direct antiandrogenic effects 
compared to other progestins, contributing to an overall 
decrease in androgen synthesis and therefore a decrease in 
acne formation.
The symptoms of PMDD are statistically significantly 
improved with the use of 3 mg DRSP/20 µg EE-24/4.
Further studies on the 3 mg DRSP/20 µg EE-24/4 
regimen will probably show additional benefits for PCOS 
patients since studies already conducted on other DRSP-
containing COCs have already proven beneficial.
In the near future DRSP may prove to be of some 
benefit for postmenopausal women in that it may be cardio-
protective. Menopausal hormone therapy containing DRSP 
may cause blood pressure reduction in hypertensive post-
menopausal women through rapid activation of endothelial 
nitric oxide synthase. These effects are mediated by action 
on both progesterone and mineralocorticoid receptors.13 The 
combination of DRSP and estrogen as menopausal hormone 
therapy for hypertensive postmenopausal women sounds 
promising, as it would have the potential to treat hot flashes 
and reduce blood pressure.16Patient Preference and Adherence 2009:3
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Therefore in the near future DRSP with a low dose estrogen 
may have its use expanded beyond that of contraception, to 
medical conditions that affect quality of life.
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